Mirae Asset Global Investments Co., Ltd. Biocryst Pharmaceuticals Inc Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 6,902 shares of BCRX stock, worth $62,463. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,902

Previous 7,483 7.76%

Holding current value

$62,463

Previous $56,000 8.93%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$7.03 - $8.43 $4,084 - $4,897	-581 Reduced 7.76%	6,902 $51,000
Q3 2024 Oct 23, 2024	BUY	$6.41 - $8.69 $8,474 - $11,488	1,322 Added 21.46%	7,483 $56,000
Q2 2024 Jul 30, 2024	SELL	$4.13 - $6.79 $544,800 - $895,689	-131,913 Reduced 95.54%	6,161 $38,000
Q1 2024 May 01, 2024	BUY	$4.89 - $7.65 $77,721 - $121,589	15,894 Added 13.01%	138,074 $701,000
Q4 2023 Jan 24, 2024	BUY	$4.98 - $6.77 $35,955 - $48,879	7,220 Added 6.28%	122,180 $731,000
Q3 2023 Oct 26, 2023	SELL	$6.71 - $7.92 $48,218 - $56,913	-7,186 Reduced 5.88%	114,960 $813,000
Q2 2023 Aug 10, 2023	BUY	$6.96 - $8.81 $13,098 - $16,580	1,882 Added 1.56%	122,146 $859,000
Q1 2023 May 04, 2023	BUY	$7.94 - $11.84 $246,282 - $367,253	31,018 Added 34.76%	120,264 $1 Million
Q4 2022 Feb 09, 2023	BUY	$10.5 - $14.2 $808 - $1,093	77 Added 0.09%	89,246 $1.02 Million
Q3 2022 Nov 10, 2022	BUY	$10.79 - $14.81 $359,673 - $493,676	33,334 Added 59.7%	89,169 $1.12 Million
Q2 2022 Jul 26, 2022	BUY	$7.89 - $17.88 $440,538 - $998,329	55,835 New	55,835 $591,000

Others Institutions Holding BCRX

# of Institutions

279

Shares Held

169M

Call Options Held

930K

Put Options Held

1.03M

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.68B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Biocryst Pharmaceuticals Inc Transaction History